Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States
CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research
pH-Triggered polymeric Nanoparticles-in-Gel for Preventing Vaginal Transmission of HIV and Unintended Pregnancy
Eur J Pharm Biopharm. 2023 Sep 3:S0939-6411(23)00234-5. doi: 10.1016/j.ejpb.2023.09.001. Online ahead of print.ABSTRACTHuman Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/ AIDS) and unplanned pregnancy affect female reproductive health globally. A single product providing a dual purpose of contraception and HIV prophylaxis may improve adherence to the therapy. Thus, we formulated a female-centric multipurpose prevention technology (MPT) comprising of nanoparticle loaded vaginal gel formulation acting as a contraceptive and microbicide. Eudragit® S100 nanoparticles of Atazanavir sulphate (ATZ; antiviral) a...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 5, 2023 Category: Drugs & Pharmacology Authors: Trinette Fernandes Vainav Patel Clara Aranha Shilpa Velhal Munira Momin Madhura Mulkutkar Sujata Sawarkar Source Type: research
pH-Triggered polymeric Nanoparticles-in-Gel for Preventing Vaginal Transmission of HIV and Unintended Pregnancy
Eur J Pharm Biopharm. 2023 Sep 3:S0939-6411(23)00234-5. doi: 10.1016/j.ejpb.2023.09.001. Online ahead of print.ABSTRACTHuman Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/ AIDS) and unplanned pregnancy affect female reproductive health globally. A single product providing a dual purpose of contraception and HIV prophylaxis may improve adherence to the therapy. Thus, we formulated a female-centric multipurpose prevention technology (MPT) comprising of nanoparticle loaded vaginal gel formulation acting as a contraceptive and microbicide. Eudragit® S100 nanoparticles of Atazanavir sulphate (ATZ; antiviral) a...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 5, 2023 Category: Drugs & Pharmacology Authors: Trinette Fernandes Vainav Patel Clara Aranha Shilpa Velhal Munira Momin Madhura Mulkutkar Sujata Sawarkar Source Type: research
Safety of misoprostol vs dinoprostone for induction of labor: A systematic review and meta-analysis
CONCLUSIONS: This systematic review and meta-analysis demonstrate that misoprostol and dinoprostone appear to have a similar safety profile.PMID:37660506 | DOI:10.1016/j.ejogrb.2023.08.382 (Source: Reproductive Biology)
Source: Reproductive Biology - September 3, 2023 Category: Reproduction Medicine Authors: Cristina Taliento Margherita Manservigi Mara Tormen Rosaria Cappadona Irene Piccolotti Stefano Salvioli Gennaro Scutiero Pantaleo Greco Source Type: research
Polyphenylene carboxymethylene (PPCM), the active component of the topical contraceptive Yaso-GEL, exhibits potent antimicrobial activity against Neisseria gonorrhoeae in preclinical studies
Conclusions
Yaso-GEL containing the API PPCM showed significant activity against N. gonorrhoeae in vitro and in vivo in a female mouse model. These data support further development of Yaso-GEL as an inexpensive, non-hormonal and non-systemic product with both contraceptive and antimicrobial activity against gonorrhea and other common sexually transmitted infections (STIs). Such multipurpose prevention technology products are needed by women in all economic, social and cultural circumstances to prevent unintended pregnancy and STIs. (Source: Sexually Transmitted Infections)
Source: Sexually Transmitted Infections - August 17, 2023 Category: Sexual Medicine Authors: Pilligua-Lucas, M., Tkavc, R., Bash, S. K., North, B. B., Weitzel, M. B., Jerse, A. E. Tags: Open access Original research Source Type: research
Cancers, Vol. 15, Pages 3863: Effect of a Multi-Ingredient Coriolus-versicolor-Based Vaginal Gel in Women with HPV & ndash;Dependent Cervical Lesions: The Papilobs Real-Life Prospective Study
The objective was to prospectively evaluate the results of using a Coriolus-versicolor-based vaginal gel (Papilocare®) on HPV-dependent low-grade cervical lesion repair in a real-life scenario. HPV-positive women ≥ 25 years with ASCUS/LSIL cervical cytology results and concordant colposcopy images were included, receiving the vaginal gel one cannula/day for 21 days (first month) + one cannula/alternate days (five months). A 6-month second treatment cycle was prescribed when needed. Repair of the cervical low-grade lesions through cytology and colposcopy, HPV clearance, and level of satisfaction, and ...
Source: Cancers - July 29, 2023 Category: Cancer & Oncology Authors: Javier Cort és Bordoy Javier de Santiago Garc ía Marta Agenjo Gonz ález Dami án Dexeus Carter Gabriel Fiol Ruiz Carmen Garc ía Ferreiro Silvia P. Gonz ález Rodríguez Marta Gurrea Soteras Ester Mart ínez Lamela Santiago Palacios Gil-Antu ñano Jos Tags: Article Source Type: research
Comparing the efficacy of vaginal micronized progesterone gel and capsule for prevention of preterm birth in singleton pregnancies with short cervical length at midtrimester: an indirect comparison meta-analysis
Conclusion: Vaginal progesterone is associated with a decreased risk of premature birth in women with a shortened cervix in the second trimester of pregnancy. No differences were found between vaginal micronized progesterone in gel or capsule formulations. Systematic Review Registration: PROSPERO, identifier CRD42020165198. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 12, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy of a 0.005% estriol vaginal gel in preventing recurrent urinary tract infections in postmenopausal women with vaginal atrophy. Blissure study
Background: Decreased estrogen levels after menopause result in vaginal atrophy, leading to elevated pH, lower levels of Lactobacilli and dysbiosis, increasing the frequency of Urinary Tract Infections (UTIs). Topical estrogens restore the atrophic vagina stimulating the proliferation of a balanced flora and preventing urinary symptoms. This preventive approach can be considered an alternative to the use of long-term antibiotics. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Nuno Aquilino Mui ños Fernández, José Ignacio Pardo González de Quevedo, Maria Pilar Diaz-Merino Martinez, Ildefonso Garcia Martin, Javier Rosado Martin, Maria Palma Santisteban, Eva Garcia Aguilar, Investigation Group Blissure Study Tags: Abstract ID: 239 Source Type: research
Polyphenylene carboxymethylene (PPCM), the active component of the topical contraceptive Yaso-GEL, exhibits potent antimicrobial activity against < em > Neisseria gonorrhoeae < /em > in preclinical studies
CONCLUSIONS: Yaso-GEL containing the API PPCM showed significant activity against N. gonorrhoeae in vitro and in vivo in a female mouse model. These data support further development of Yaso-GEL as an inexpensive, non-hormonal and non-systemic product with both contraceptive and antimicrobial activity against gonorrhea and other common sexually transmitted infections (STIs). Such multipurpose prevention technology products are needed by women in all economic, social and cultural circumstances to prevent unintended pregnancy and STIs.PMID:37156608 | DOI:10.1136/sextrans-2022-055596 (Source: Herpes)
Source: Herpes - May 8, 2023 Category: Infectious Diseases Authors: Michelle Pilligua-Lucas Rok Tkavc Sarah K Bash Barbara B North Mary B Weitzel Ann E Jerse Source Type: research
Effects of two different types of luteal support on pregnancy outcomes following antagonist fresh embryo transfer: a retrospective study
Only a small number of studies have reported the use of progesterone vaginal gel in combination with dydrogesterone as part of the antagonist protocol for fresh embryo transfer. Therefore, this study aimed to ... (Source: BMC Pregnancy and Childbirth)
Source: BMC Pregnancy and Childbirth - May 4, 2023 Category: OBGYN Authors: Minji De, Lixue Chen, Lin Zeng, Yang Wang, Rui Yang, Rong Li and Hongbin Chi Tags: Research Source Type: research
Acceptability of Single-Dose Clindamycin Gel for Bacterial Vaginosis: A Randomized Controlled Trial
Clin Ther. 2023 Apr 23:S0149-2918(23)00130-3. doi: 10.1016/j.clinthera.2023.04.001. Online ahead of print.ABSTRACTPURPOSE: The goal of this study was to assess the acceptability of a single-dose bioadhesive 2% clindamycin vaginal gel for bacterial vaginosis (BV).METHODS: This double-blind, placebo-controlled, randomized study compared a new clindamycin gel with placebo gel (2:1 ratio). The primary objective was efficacy; secondary objectives were safety and acceptability. Subjects were evaluated at screening, days 7 to 14 (Day 7-14), and days 21 to 30 (test-of-cure [TOC]). An acceptability questionnaire with 9 questions wa...
Source: Clinical Therapeutics - April 25, 2023 Category: Drugs & Pharmacology Authors: Christine Mauck Sharon L Hillier Judy Gendreau Clint Dart Hongsheng Wu Steven Chavoustie Valerie Sorkin-Wells Clifton Scott Nicholson-Uhl Brandon Perez Mark Jacobs Nadene Zack David Friend Source Type: research
Acceptability of Single-Dose Clindamycin Gel for Bacterial Vaginosis: A Randomized Controlled Trial
Clin Ther. 2023 Apr 23:S0149-2918(23)00130-3. doi: 10.1016/j.clinthera.2023.04.001. Online ahead of print.ABSTRACTPURPOSE: The goal of this study was to assess the acceptability of a single-dose bioadhesive 2% clindamycin vaginal gel for bacterial vaginosis (BV).METHODS: This double-blind, placebo-controlled, randomized study compared a new clindamycin gel with placebo gel (2:1 ratio). The primary objective was efficacy; secondary objectives were safety and acceptability. Subjects were evaluated at screening, days 7 to 14 (Day 7-14), and days 21 to 30 (test-of-cure [TOC]). An acceptability questionnaire with 9 questions wa...
Source: Clinical Therapeutics - April 25, 2023 Category: Drugs & Pharmacology Authors: Christine Mauck Sharon L Hillier Judy Gendreau Clint Dart Hongsheng Wu Steven Chavoustie Valerie Sorkin-Wells Clifton Scott Nicholson-Uhl Brandon Perez Mark Jacobs Nadene Zack David Friend Source Type: research
